Literature DB >> 28772294

Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.

Marielle W G Ruijs1, Claudette E Loo2, Colette A J M van Buchem2, Eveline M A Bleiker3, Gabe S Sonke4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28772294      PMCID： PMC5824278          DOI： 10.1001/jamaoncol.2017.1346

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

2.  Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.

Authors:  K E Nichols; D Malkin; J E Garber; J F Fraumeni; F P Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-02       Impact factor: 4.254

3.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

Authors:  Anita Villani; Ari Shore; Jonathan D Wasserman; Derek Stephens; Raymond H Kim; Harriet Druker; Bailey Gallinger; Anne Naumer; Wendy Kohlmann; Ana Novokmet; Uri Tabori; Marta Tijerin; Mary-Louise C Greer; Jonathan L Finlay; Joshua D Schiffman; David Malkin
Journal:  Lancet Oncol       Date:  2016-08-05       Impact factor: 41.316

5.  Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management.

Authors:  Katrin Hegenscheid; Rebecca Seipel; Carsten O Schmidt; Henry Völzke; Jens-Peter Kühn; Reiner Biffar; Heyo K Kroemer; Norbert Hosten; Ralf Puls
Journal:  Eur Radiol       Date:  2012-08-22       Impact factor: 5.315
  5 in total
  7 in total

Review 1.  [Update on Li-Fraumeni syndrome].

Authors:  C M Dutzmann; J Vogel; C P Kratz; K W Pajtler; S M Pfister; B B Dörgeloh
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

2.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

3.  Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.

Authors:  J J Bakhuizen; M E Velthuizen; S Stehouwer; E M Bleiker; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

4.  Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.

Authors:  Thierry Frebourg; Svetlana Bajalica Lagercrantz; Carla Oliveira; Rita Magenheim; D Gareth Evans
Journal:  Eur J Hum Genet       Date:  2020-05-26       Impact factor: 4.246

5.  Blood functional assay for rapid clinical interpretation of germline TP53 variants.

Authors:  Sabine Raad; Marion Rolain; Sophie Coutant; Céline Derambure; Raphael Lanos; Françoise Charbonnier; Jacqueline Bou; Emilie Bouvignies; Gwendoline Lienard; Stéphanie Vasseur; Michael Farrell; Olivier Ingster; Stéphanie Baert Desurmont; Edwige Kasper; Gaëlle Bougeard; Thierry Frébourg; Isabelle Tournier
Journal:  J Med Genet       Date:  2020-10-13       Impact factor: 6.318

6.  Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53.

Authors:  Emma Tham; Svetlana Bajalica-Lagercrantz; Meis Omran; Lennart Blomqvist; Yvonne Brandberg; Niklas Pal; Per Kogner; Anne Kinhult Ståhlbom
Journal:  Hered Cancer Clin Pract       Date:  2020-01-13       Impact factor: 2.857

7.  Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53).

Authors:  Meis Omran; Emma Tham; Yvonne Brandberg; Håkan Ahlström; Claudia Lundgren; Ylva Paulsson-Karlsson; Ekaterina Kuchinskaya; Gustav Silander; Anna Rosén; Fredrik Persson; Henrik Leonhardt; Marie Stenmark-Askmalm; Johanna Berg; Danielle van Westen; Svetlana Bajalica-Lagercrantz; Lennart Blomqvist
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.